Related Experiment Video

Updated: May 2, 2026

Novel and Innovative Hybrid Technique for Type A Aortic Dissection
06:26

Novel and Innovative Hybrid Technique for Type A Aortic Dissection

Published on: March 28, 2025

1.4K

First-line beta-blockers versus other antihypertensive medications for chronic type B aortic dissection

Kenneth K Chan1, Peggy Lai, James M Wright

  • 1Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

The Cochrane Database of Systematic Reviews
|February 27, 2014
PubMed

Insights

No randomized controlled trials (RCTs) were found comparing beta-blockers with other antihypertensives for chronic type B aortic dissection. Further RCTs are needed to evaluate current treatment guidelines for this condition.

Area of Science:

  • Cardiovascular Medicine
  • Hypertension Research
  • Aortic Disease Management

Background:

  • Thoracic aortic dissection (TAD) is a life-threatening condition often linked to hypertension.
  • Beta-blockers are the current first-line treatment for chronic type B TAD to reduce aortic stress.
  • Alternative antihypertensives like CCBs, ACE inhibitors, and ARBs have been proposed for TAD management.

Purpose of the Study:

  • To compare the efficacy of first-line beta-blockers against other antihypertensive drug classes in treating chronic type B TAD.
  • To identify evidence supporting or refuting current treatment guidelines for chronic type B TAD.

Main Methods:

  • A systematic review of randomized controlled trials (RCTs) was conducted.
  • Searches were performed across multiple databases including Cochrane, MEDLINE, EMBASE, and ClinicalTrials.gov.
  • The primary outcome was total mortality; secondary outcomes included non-fatal adverse events and need for surgery.

Main Results:

  • No RCTs met the inclusion criteria for this review.
  • There is a lack of direct comparative evidence for first-line antihypertensive therapies in chronic type B TAD.

Conclusions:

  • Current guidelines recommending beta-blockers for chronic type B TAD lack RCT-based evidence.
  • High-quality RCTs are essential to determine the optimal first-line antihypertensive treatment for chronic type B TAD.
  • Further research is needed to assess the comparative benefits and risks of different antihypertensive medications.
Abstract

More Related Videos

Murine Model of Thoracic Aortic Dissection Induced by Oral β-Aminopropionitrile and Subcutaneous Angiotensin II Infusion05:31

Murine Model of Thoracic Aortic Dissection Induced by Oral β-Aminopropionitrile and Subcutaneous Angiotensin II Infusion

Published on: May 16, 2025

1.3K
Author Spotlight: Development of a Minimally Invasive Large-Animal Model for Reliable and Reproducible Cardiovascular Research06:51

Author Spotlight: Development of a Minimally Invasive Large-Animal Model for Reliable and Reproducible Cardiovascular Research

Published on: October 20, 2023

1.8K

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K